Pircher Magdalena, Winder Thomas, Trojan Andreas
Onkozentrum Zürich, Zurich, Switzerland.
Swiss Tumor Molecular Institute, Zurich, Switzerland.
Case Rep Oncol. 2021 Mar 29;14(1):616-621. doi: 10.1159/000513905. eCollection 2021 Jan-Apr.
Effective treatment options are still scarce for metastatic triple-negative breast cancers. An increasing interest in the mutational landscape of this disease will facilitate novel therapeutic strategies in a variety of cancers. Here we report the case of a 38-year-old female patient who developed multiple lung metastasis of a triple-negative breast cancer 2 years after the completion of local therapy. When she progressed after two palliative chemotherapy lines and local electroporation, a next-generation sequencing revealed a BRAF V600E mutation for which we initiated therapy with the BRAF inhibitor vemurafenib. Radiological improvement was already evident after 3 months and has been ongoing for 19 months so far with very few side effects, as is demonstrated by electronically captured patient-reported outcomes. To our knowledge, this is the first published case where a BRAF V600E-mutated advanced triple-negative breast cancer was successfully treated with vemurafenib.
对于转移性三阴性乳腺癌，有效的治疗选择仍然匮乏。对该疾病突变图谱的兴趣日益增加，这将推动多种癌症的新型治疗策略的发展。在此，我们报告一例38岁女性患者，其在局部治疗完成2年后发生了三阴性乳腺癌的多处肺转移。在接受两线姑息化疗和局部电穿孔治疗后病情进展，二代测序显示存在BRAF V600E突变，为此我们开始使用BRAF抑制剂维莫非尼进行治疗。3个月后影像学改善已很明显，迄今为止已持续了19个月，副作用极少，电子记录的患者报告结局证明了这一点。据我们所知，这是首例发表的使用维莫非尼成功治疗BRAF V600E突变的晚期三阴性乳腺癌的病例。
